Daratumumab, a first in class anti-CD38 antibody, is currently approved both as monotherapy and combination therapy for relapsed/refractory MM (r/r MM) and has shown remarkable activity also in the first-line setting, both for transplant eligible [6] and ineligible [7,8] patients. The gene discussed is CD38; the disease is Miyoshi myopathy.